In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of γ-hydroxybutyrate (GHB) binding

K. R. Vogel, G. R. Ainslie, Jean-Baptiste Roullet, A. McConnell, K. M. Gibson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

γ-Hydroxybutyric acid (GHB), a minor metabolite of the inhibitory neurotransmitter GABA, can accumulate to significant concentrations in the heritable disorder of GABA degradation, succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD). Moreover, GHB may be employed in therapeutic settings (treatment of narcolepsy), as well as instances of illicit activity, including acquaintance sexual assault and the induction of euphoria. High-affinity binding sites for GHB in the brain have been identified, although the absolute identity of these receptors remains unclear. Pharmacological antagonism of GHB binding may have multiple instances of therapeutic relevance. The high affinity GHB receptor antagonist, NCS-382 (6,7,8,9-tetrahydro-5-hydroxy-5H-benzo-cyclohept-6-ylideneacetic acid) has not been piloted in humans. To address the potential clinical utility of NCS-382, we have piloted initial studies of its toxicology in HepG2 and primary hepatocyte cells. At high dose (0.5 mM), NCS-382 showed no capacity for inhibition of microsomal CYPs (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4) and minimal potential for activation of xenobiotic nuclear receptors. Additional cellular integrity and functional assays (viability, oxidative stress, apoptosis, ATP production) revealed little evidence for cytotoxicity, and a low degree of dysregulation of > 370 genes actively engaged in the mediation of cellular toxicity. In vitro testing indicates a low probability of cellular toxicity associated with NCS-382.

Original languageEnglish (US)
Pages (from-to)196-202
Number of pages7
JournalToxicology in Vitro
Volume40
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Hydroxybutyrates
Toxicology
gamma-Aminobutyric Acid
Toxicity
Succinate-Semialdehyde Dehydrogenase
Narcolepsy
Cytochrome P-450 CYP1A2
Oxidative stress
Xenobiotics
Cytotoxicity
Cytoplasmic and Nuclear Receptors
Metabolites
Neurotransmitter Agents
Hepatocytes
Assays
Brain
Oxidative Stress
Therapeutics
Genes
Adenosine Triphosphate

Keywords

  • Apoptosis
  • Cytochrome P-450 (CYP)
  • Cytotoxicity
  • Gene expression
  • HepG2 cells
  • Microsomal CYPs
  • Mitochondrial function
  • Primary human hepatocytes
  • PXR
  • Xenobiotic receptor induction

ASJC Scopus subject areas

  • Toxicology

Cite this

In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of γ-hydroxybutyrate (GHB) binding. / Vogel, K. R.; Ainslie, G. R.; Roullet, Jean-Baptiste; McConnell, A.; Gibson, K. M.

In: Toxicology in Vitro, Vol. 40, 01.04.2017, p. 196-202.

Research output: Contribution to journalArticle

Vogel, K. R. ; Ainslie, G. R. ; Roullet, Jean-Baptiste ; McConnell, A. ; Gibson, K. M. / In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of γ-hydroxybutyrate (GHB) binding. In: Toxicology in Vitro. 2017 ; Vol. 40. pp. 196-202.
@article{0a1ef60a8e0b4d0c875f0dad376b1f7b,
title = "In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of γ-hydroxybutyrate (GHB) binding",
abstract = "γ-Hydroxybutyric acid (GHB), a minor metabolite of the inhibitory neurotransmitter GABA, can accumulate to significant concentrations in the heritable disorder of GABA degradation, succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD). Moreover, GHB may be employed in therapeutic settings (treatment of narcolepsy), as well as instances of illicit activity, including acquaintance sexual assault and the induction of euphoria. High-affinity binding sites for GHB in the brain have been identified, although the absolute identity of these receptors remains unclear. Pharmacological antagonism of GHB binding may have multiple instances of therapeutic relevance. The high affinity GHB receptor antagonist, NCS-382 (6,7,8,9-tetrahydro-5-hydroxy-5H-benzo-cyclohept-6-ylideneacetic acid) has not been piloted in humans. To address the potential clinical utility of NCS-382, we have piloted initial studies of its toxicology in HepG2 and primary hepatocyte cells. At high dose (0.5 mM), NCS-382 showed no capacity for inhibition of microsomal CYPs (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4) and minimal potential for activation of xenobiotic nuclear receptors. Additional cellular integrity and functional assays (viability, oxidative stress, apoptosis, ATP production) revealed little evidence for cytotoxicity, and a low degree of dysregulation of > 370 genes actively engaged in the mediation of cellular toxicity. In vitro testing indicates a low probability of cellular toxicity associated with NCS-382.",
keywords = "Apoptosis, Cytochrome P-450 (CYP), Cytotoxicity, Gene expression, HepG2 cells, Microsomal CYPs, Mitochondrial function, Primary human hepatocytes, PXR, Xenobiotic receptor induction",
author = "Vogel, {K. R.} and Ainslie, {G. R.} and Jean-Baptiste Roullet and A. McConnell and Gibson, {K. M.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.tiv.2017.01.013",
language = "English (US)",
volume = "40",
pages = "196--202",
journal = "Toxicology in Vitro",
issn = "0887-2333",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of γ-hydroxybutyrate (GHB) binding

AU - Vogel, K. R.

AU - Ainslie, G. R.

AU - Roullet, Jean-Baptiste

AU - McConnell, A.

AU - Gibson, K. M.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - γ-Hydroxybutyric acid (GHB), a minor metabolite of the inhibitory neurotransmitter GABA, can accumulate to significant concentrations in the heritable disorder of GABA degradation, succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD). Moreover, GHB may be employed in therapeutic settings (treatment of narcolepsy), as well as instances of illicit activity, including acquaintance sexual assault and the induction of euphoria. High-affinity binding sites for GHB in the brain have been identified, although the absolute identity of these receptors remains unclear. Pharmacological antagonism of GHB binding may have multiple instances of therapeutic relevance. The high affinity GHB receptor antagonist, NCS-382 (6,7,8,9-tetrahydro-5-hydroxy-5H-benzo-cyclohept-6-ylideneacetic acid) has not been piloted in humans. To address the potential clinical utility of NCS-382, we have piloted initial studies of its toxicology in HepG2 and primary hepatocyte cells. At high dose (0.5 mM), NCS-382 showed no capacity for inhibition of microsomal CYPs (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4) and minimal potential for activation of xenobiotic nuclear receptors. Additional cellular integrity and functional assays (viability, oxidative stress, apoptosis, ATP production) revealed little evidence for cytotoxicity, and a low degree of dysregulation of > 370 genes actively engaged in the mediation of cellular toxicity. In vitro testing indicates a low probability of cellular toxicity associated with NCS-382.

AB - γ-Hydroxybutyric acid (GHB), a minor metabolite of the inhibitory neurotransmitter GABA, can accumulate to significant concentrations in the heritable disorder of GABA degradation, succinic semialdehyde dehydrogenase (SSADH) deficiency (SSADHD). Moreover, GHB may be employed in therapeutic settings (treatment of narcolepsy), as well as instances of illicit activity, including acquaintance sexual assault and the induction of euphoria. High-affinity binding sites for GHB in the brain have been identified, although the absolute identity of these receptors remains unclear. Pharmacological antagonism of GHB binding may have multiple instances of therapeutic relevance. The high affinity GHB receptor antagonist, NCS-382 (6,7,8,9-tetrahydro-5-hydroxy-5H-benzo-cyclohept-6-ylideneacetic acid) has not been piloted in humans. To address the potential clinical utility of NCS-382, we have piloted initial studies of its toxicology in HepG2 and primary hepatocyte cells. At high dose (0.5 mM), NCS-382 showed no capacity for inhibition of microsomal CYPs (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4) and minimal potential for activation of xenobiotic nuclear receptors. Additional cellular integrity and functional assays (viability, oxidative stress, apoptosis, ATP production) revealed little evidence for cytotoxicity, and a low degree of dysregulation of > 370 genes actively engaged in the mediation of cellular toxicity. In vitro testing indicates a low probability of cellular toxicity associated with NCS-382.

KW - Apoptosis

KW - Cytochrome P-450 (CYP)

KW - Cytotoxicity

KW - Gene expression

KW - HepG2 cells

KW - Microsomal CYPs

KW - Mitochondrial function

KW - Primary human hepatocytes

KW - PXR

KW - Xenobiotic receptor induction

UR - http://www.scopus.com/inward/record.url?scp=85010782766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010782766&partnerID=8YFLogxK

U2 - 10.1016/j.tiv.2017.01.013

DO - 10.1016/j.tiv.2017.01.013

M3 - Article

C2 - 28119166

AN - SCOPUS:85010782766

VL - 40

SP - 196

EP - 202

JO - Toxicology in Vitro

JF - Toxicology in Vitro

SN - 0887-2333

ER -